Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants

Pertussis Clinical Trial

Official title:

Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy Infants 3 to 5 Months of Age: A Randomized, Blinded, Single-center, Positive Controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02477995
• Other study ID #: 1110103
• Status: Completed
• Phase: Phase 3
• First received: June 9, 2015
• Last updated: June 22, 2015
• Start date: December 2013
• Est. completion date: July 2014

Study information

• Verified date: July 2011
• Source: Jiangsu Province Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Pertussis, diphtheria and tetanus are seriously infectious diseases in children. Since using of the adsorption diphtheria-tetanus-whole-cell pertussis (DTwP), it greatly reduced incidence of the three kinds of diseases. But the thallus of pertussis in the vaccine may cause more side reactions after vaccination. Since 2000, the basic immunization DTwP vaccine has been replaced by adsorption tetanus-diphtheria-acellular pertussis vaccine in American. In 1995, DTaP was successfully developed in China, and have been used in EPI at present. Because of effective immunity and little side reaction, DTaP has been widely recognized and accepted by the parents.

Description:

Pertussis, diphtheria and tetanus are seriously infectious diseases for children. The world health organization (WHO) included the adsorption diphtheria-tetanus-whole-cell pertussis (DTwP) into the expanded program on immunization (EPI), as a basic immunization. Since using the DTwP, it greatly reduced incidence of the three kinds of diseases. Thousands of children have been saved since its application. Although the DTwP was productively in against pertussis, diphtheria and tetanus, thallus of pertussis in the vaccine could cause more side reactions after vaccination. Many individuals did not want to be vaccinated. However, there was two large epidemics of pertussis during the period of 1977-1979 and 1981-1983. Since 2000, the basic immunization DTwP vaccine has been replaced by adsorption tetanus-diphtheria-acellular pertussis vaccine (DTaP) vaccine in American. In 1995, DTaP was successful developed in the investigators' country, and is used in EPI at present. Because of effective immunity and causing little side reaction, DTaP has been widely recognized and accepted by the parents. This clinical trial is planning to evaluate the immunogenicity and safety of DTaP in 3-5 months infants .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: July 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Months to 5 Months

Eligibility

Inclusion criteria:

• Healthy infants aged 3-5months old as established by medical history and clinical examination

• The subjects' guardians are able to understand and sign the informed consent

• Subjects who can and will comply with the requirements of the protocol

• Subjects with temperature =37.0°C on axillary setting

Exclusion criteria:

• Subjects who was premature birth

• Subjects who has a medical history of diphtheria, pertussis or tetanus.

• Had been vaccined for DTwP or DTaP

• Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine

• Severe malnutrition or dysgenopathy

• Family history of seizures or progressive neurological disease

• Family history of congenital or hereditary immunodeficiency

• Thyroid disease

• Coagulation disorder diagnosed by a doctor(such as the lack of clotting factors, clotting hemorrhagic disease, platelet abnormalities) or significant bruising

• No spleen, functional asplenia, and any situation caused by no spleen or splenectomy

• Any acute infections in last 7 days

• Any prior administration of immunodepressant or corticosteroids

• Any prior administration of blood products in last 3 month

• Any prior administration of other research medicines in last 1 month

• Any prior administration of attenuated live vaccine in last 15 days

• Any prior administration of subunit or inactivated vaccines in last 7 days

• Had fever before vaccination, Subjects with temperature >37.0°C on axillary setting

• Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Exclusion criteria for the second and third dose:

If subjects who have one condition of 1 to 4 as followed, prohibiting to continue the vaccination, and they will be continue observed in the opinion of the investigator. If Subjects who had one condition of 5 to 6 as followed, must be determined whether to continue by the investigator. If Subjects who had one condition of 7 to 8 as followed, they can had a delayed vaccination during time frame of the program. All participants with adverse events as followed, must be settled in follow-up to the end of events.

• Any serious adverse events caused by vaccination.

• Hypersensitivity after vaccination.

• Anaphylaxis after vaccination

• Any confirmed or suspected autoimmune diseases or immune deficiency disorders, including human immunodeficiency virus (HIV) infection

• Have acute or new chronic disease during vaccination

• Other reactions that in the opinion of the investigator ( include: severely serious symptom of pain, swelling, Limitation of motion, continuous high fever, headache and other Systemic or local reactions )

• Have acute disease during vaccination (Acute disease refers to with or without fever of moderate or severe disease)

• Subjects with temperature >37.0°C on axillary settin.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Pertussis
• Whooping Cough

Intervention

Biological:
• DTaP Vaccine A
Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
• DTaP Vaccine B
Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.

Locations

Country	Name	City	State
China	Jiangsu Provincial Center for Diseases Control and Prevention	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Province Centers for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity after vaccination	The seroconversion rate of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibody on day 28 post-dose 3.; seroconversion is defined as post-third dose anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibody concentrations = protective antibody concentration, if pre-vaccination concentration is < protective antibody concentration or = 4 x protective antibody concentration if pre- vaccination concentrations = protective antibody concentration.	Day 28 post-dose 3	No
Primary	Proportion of subjects reporting solicited injection-site reactions, solicited systemic reactions.	Proportion of subjects reporting solicited injection-site reactions, solicited systemic reactions on day 7 post-each dose.	Day 7 post-each dose	Yes
Secondary	The seropositivity rates of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibodies in serum on day 28 post-dose3.	The seropositive rates of anti-pertussis tox oid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibodies in serum on day 28 post-dose3. Seropositivity is defined as post-third dose anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibody concentrations = protective antibody concentration.	Day 28 post-dose 3	No
Secondary	Proportion of subjects reporting unsolicited injection-site and systemic reactions.		Day 28 post-each dose	Yes
Secondary	Proportion of subjects with serious adverse events(SAE) occurring throughout the trial.		Day 0 up to 90 post-vaccination	Yes
Secondary	Geometric mean concentration(GMC)of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibodies in serum on day 28 post-dose3.		Day 28 post-dose 3	No
Secondary	Geometric mean fold increase(GMFI)of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibodies in serum on day 28 post-dose3.		Day 28 post-dose 3	No